Product Information
DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Ascend Laboratories, LLC, priced at $0.9198 per EA under NDC 67877062460. Its NADAC has been published 30 times since Dec 3, 2025.
Strength
110 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877062460
Classification
Generic
Dosage Form
CAPSULE, COATED PELLETS
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208040On Market Since
9/12/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 30 times since Dec 3, 2025, and over the history we have for it it has declined 42.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9198 per EA |
|---|---|
| All-time high | $1.6053 (Dec 10, 2025) |
| All-time low | $0.9196 (May 20, 2026) |
| 52-week high | $1.6053 |
| 52-week low | $0.9196 |
| Median price | $1.0687 |
| Average price | $1.1365 |
| Largest weekly change | -12.4% (Dec 17, 2025) |
| Weeks tracked | 30 |
| Tracking since | Dec 3, 2025 |
Generic Alternatives
The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Ascend Laboratories, LLC, is $0.9198 per EA (NDC 67877062460), effective Jun 24, 2026.
How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 42.7%. It has been tracked across 30 weekly CMS publications since Dec 3, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?
Since Dec 3, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.6053 (Dec 10, 2025), with a median of $1.0687 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?
3 NADAC-published products share the same active ingredient, strength, and dosage form as DABIGATRAN ETEXILATE 110 MG CP, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 110 MG CP?
DABIGATRAN ETEXILATE 110 MG CP (NDC 67877062460) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification